MedPath

Nurse-led Intervention to Improve Phosphate Binder Adherence

Not Applicable
Completed
Conditions
End Stage Renal Failure on Dialysis
Interventions
Behavioral: Adherence support
Registration Number
NCT02063490
Lead Sponsor
Universiteit Antwerpen
Brief Summary

The study aim is to test the efficacy of one-year nurse-led interventions to improve the medication intake behaviour of chronic dialysis patients. The investigators hypothesis is the interventions leading to a 15% mean increase in intake, compared to standard care.

Detailed Description

Background Phosphate binder nonadherence is ubiquitous. The results of adherence enhancing interventions are often disappointing. The aim is to test a nurse-led multifactorial intervention to enhance phosphate binder adherence.

Methods In a quasi-experimental clinical trial, phosphate binder adherence was measured electronically in 135 hemodialysis patients for one year and phosphatemia measured monthly. For all patients, months 1-2 were baseline (no interventions were performed). The intervention arm was given 1 "preparatory" intervention and then monthly 8 "maintenance" individualized management sessions. The control arm received standard of care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
135
Inclusion Criteria
  • adult (≥18)
  • chronic hemodialysis ≥1 month
  • treated with phosphate binders
  • Dutch-speaking
Exclusion Criteria
  • receiving professional medication care
  • cognitive impairment
  • nursing home residents

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Adherence supportAdherence supportOne-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills) + One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions
Primary Outcome Measures
NameTimeMethod
Medication adherenceOne year

The intake of medication (phosphate binders) was monitored continuously for one year through electronic monitoring with the Medication Event Monitoring System (MEMS). Medication containers are filled with patients' phosphate binders and then capped with MEMS-caps registering the time and date of each opening and thus presumed intake of the medication in the box.

Mean adherence was calculated as the proportion of prescribed doses taken, averaged per month (e.g. patients with a ter in die regimen (84 doses/month) and taking them all 84 would have a mean adherence of 84/84=100%). Nonadherence was defined as a mean adherence \<80%.

Secondary Outcome Measures
NameTimeMethod
Serum phosphateMonthly for one year

Serum phosphate was gathered monthly from patients' charts. In addition to mean serum phosphate per month we dichtomised this outcome measure with \>5mg/dL representing uncontrolled phosphatemia.

Patient knowledgeAt study start and end (after one year)

Knowledge was measured by ten multiple-choice questions about the phosphate cycle, phosphate binder pharmacodynamics and dietary recommendations, developed in previous research and added as appendix in a previous article (Van Camp Y, Vrijens B, Abraham I, et al. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol 2013; JNEPHROL-D-13-00176R1: Publicatin in process)

Social supportAt study start and end (after one year)

Social support was measured by eleven questions assessing perceived support in general and support with taking phosphate binders specifically, developed in previous research and added as appendix in a previous article (Van Camp Y, Vrijens B, Abraham I, et al. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol 2013; JNEPHROL-D-13-00176R1: publication in process)

Trial Locations

Locations (3)

Dialysis hospital unit 3

🇧🇪

Antwerpen, Belgium

Dialysis hospital unit 1

🇧🇪

Antwerpen, Belgium

Dialysis hospital unit 2

🇧🇪

Turnhout, Belgium

© Copyright 2025. All Rights Reserved by MedPath